Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspen to Pay UK NHS £8m In Landmark Deal Following Competition Probe

Executive Summary

Aspen has agreed to pay the National Health Service £8m following an investigation by the Competition and Markets Authority.

You may also be interested in...



US, EU and UK Antitrust Enforcers Form Pharma Monitoring Taskforce

Antitrust regulators in the US, Europe and elsewhere say they will now collaborate on how to best assess pharmaceutical mergers, in a move that could restrict deals on grounds they excessively raise prices paid by consumers or dampen medical innovation. 

UK’s CMA Issues Fines Over Fludrocortisone

The UK’s Competition and Markets Authority has issued fines of nearly £2.3m after formally concluding that three firms participated in illegal arrangements over fludrocortisone that violated competition law.

Netherlands Gives Funding Nod To CGRP Inhibitors For Chronic Migraines

The Dutch health technology appraisal body, ZIN, said Novartis’ Aimovig should be reimbursed for the treatment of chronic migraine after initially advising against it.

Topics

Related Companies

UsernamePublicRestriction

Register

PS140681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel